3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Fluorouracil
155
Oxaliplatin
133
Leucovorin
124
Capecitabine
90
Irinotecan
88
Radiotherapy
63
Bevacizumab
61
Cetuximab
38
Folfox protocol
25
Panitumumab
21
Neoadjuvant Therapy
21
Surgical Procedures, Operative
19
Chemotherapy, Adjuvant
15
Radiation
13
Floxuridine
13
Erlotinib Hydrochloride
13
Early Intervention, Educational
13
IFL protocol
11
Drug Therapy
11
Proctectomy
10
Magnetic Resonance Spectroscopy
10
Counseling
10
Surveys and Questionnaires
8
Sorafenib
8
Psychiatric Rehabilitation
8
Gene Expression Profiling
8
Radiotherapy, Intensity-Modulated
7
Immunohistochemistry
7
Gemcitabine
7
Celecoxib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Rectal Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled